We are Providing Therapeutic Innovation to Control Dysregulated Inflammation
Inter-alpha Inhibitor Proteins (IAIP)
Highly innovative, disease-modifying treatments for inflammatory conditions
Severe Community Acquired Pneumonia
The Leading Cause of Death from Infection in the US
Severe pneumonia patients require an ICU stay and mechanical ventilation. Very high death rates are associated this serious condition. Young children and older adults are at higher risk for severe pneumonia and no therapeutics are available to treat the effects of the damaging inflammation.
The #1 cause of disability in the US
Stroke can lead to the inability to move one side of the body, problems with thinking and memory and neuropsychiatric problems such as depression, anxiety, fatigue. It can also result in death. Stroke is a disease with a very fast onset and only one marketed drug is available. There are no medications available to treat the damaging inflammation.
ProThera’s Therapeutic IAIP will also be used to treat diseases with very small patient populations, “orphan diseases”
Neonatal Hypoxic Ischemic Brain Injury
A leading cause of death and neurologic disability in infant
Neonatal Hypoxic Ischemic Brain Injury can lead to mental retardation, cerebral palsy, epilepsy, and life-long neurological disabilities. There are multiple risk factors for neonatal hypoxic brain injury including maternal acute high or low blood pressure and interrupted breathing or poor oxygen supply. No treatments are available for pre term infants with this condition and the only treatment available for full terms infants is the use of a cooling blanket which is only partially effective. There are no treatments available for the damaging inflammation. Neonatal Hypoxic Brain Injury is considered an orphan indication.
A significant cause of death among term and preterm infants
Neonatal sepsis results from an invasive infection and significant mortality occurs especially among very low birth weight infants in Neonatal Intensive Care Units. The signs and symptoms of neonatal sepsis are nonspecific and early diagnosis and prompt treatment remains a significant challenge.
ProThera Biologics is developing IAIP as a biomarker with high accuracy to rapidly discern infant patients at risk for sepsis.
We are committed to enabling long and healthy lives.
IAIP replacement Therapy and Biomarker Rapid Test: To rapidly detect, modify and reverse the course of disease.